Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.37B 2.95B 2.72B 2.52B 4.77B 321B 4.85B 32.52B 12.76B 158B 12.65B 12.38B 545B P/E 2026 *
-45.8x
P/E 2027 * -86x
Enterprise Value 3.24B 2.84B 2.61B 2.42B 4.58B 309B 4.66B 31.23B 12.25B 152B 12.15B 11.88B 523B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 9.08x
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
1 day-3.39%
1 week-0.61%
Current month-1.82%
1 month+23.37%
3 months+64.66%
6 months+33.63%
Current year+29.68%
1 week 19.77
Extreme 19.7711
22.13
1 month 15.9
Extreme 15.9
22.8
Current year 12
Extreme 12
22.8
1 year 9.96
Extreme 9.9551
22.8
3 years 2.28
Extreme 2.28
22.8
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Head of Human Resources

120,564 0.0753%
07-01Sell

Founder

-386,240 0.2413%
06-30Sell

Executive/Senior Manager

-487 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-3.39%-0.61%+74.34%+222.02% 3.49B
-3.93%-0.19%+107.01%+125.98% 4.73B
+4.20%+0.98%-26.76%-38.58% 1.96B
-3.20%-1.86%+119.17%-51.88% 1.95B
-2.06%-2.33%+38.20%+193.61% 1.5B
+6.42%+0.17%-9.66%+49.25% 822M
+2.01%+0.83%+110.73%-50.12% 881M
+1.63%-0.94%-36.02%-17.66% 474M
+7.05%+0.24%-3.85% - 452M
+13.46%-3.10% - - 171M
Average +2.22%+0.70%+41.46%+54.08% 1.64B
Weighted average by Cap. -1.11%+1.76%+66.02%+93.13%

Financials

2026 *2027 *
Net sales 287M 252M 232M 214M 406M 27.39B 413M 2.77B 1.09B 13.49B 1.08B 1.05B 46.43B 352M 308M 284M 263M 498M 33.58B 507M 3.4B 1.33B 16.54B 1.32B 1.29B 56.93B
Net income -71.88M -62.97M -58.06M -53.65M -102M -6.85B -103M -694M -272M -3.38B -270M -264M -11.62B -37.9M -33.21M -30.62M -28.29M -53.64M -3.61B -54.54M -366M -143M -1.78B -142M -139M -6.13B
Net Debt -135M -118M -109M -100M -190M -12.84B -194M -1.3B -509M -6.32B -505M -494M -21.76B -173M -151M -139M -129M -244M -16.46B -248M -1.67B -653M -8.11B -648M -634M -27.9B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-07-10 US$21.06 -3.39% 1,907,290
26-07-09 US$21.80 +8.13% 3,005,961
26-07-08 US$20.16 -3.17% 2,513,999
26-07-07 US$20.82 -3.16% 2,440,474
26-07-06 US$21.50 +1.46% 2,525,680
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.80USD
Average target price
20.57USD
Spread / Average Target
-5.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock